Betovumeline

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C8H11N3O
Molecular Weight	165.1924
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NOC(=N1)[C@]23C[C@H]2CNC3

InChI

InChIKey=FTFZIXZMGKRLHO-XPUUQOCRSA-N

InChI=1S/C8H11N3O/c1-5-10-7(12-11-5)8-2-6(8)3-9-4-8/h6,9H,2-4H2,1H3/t6-,8-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C8H11N3O
Molecular Weight	165.1924
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Wed Apr 02 21:09:59 GMT 2025` Edited by `admin` on `Wed Apr 02 21:09:59 GMT 2025`
Record UNII	5UXW4B47R9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(1R,5R)-1-(3-Methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.1.0]hexane

Preferred Name

English

Betovumeline

Official Name

English

MPL-0527 free base

Code

English

betovumeline [INN]

Common Name

English

3-Azabicyclo[3.1.0]hexane, 1-(3-methyl-1,2,4-oxadiazol-5-yl)-, (1R,5R)-

Common Name

English

MPL0527 free base

Code

English

Code System Code Type Description

PUBCHEM

86699317

Created by admin on Wed Apr 02 21:09:59 GMT 2025 , Edited by admin on Wed Apr 02 21:09:59 GMT 2025

PRIMARY

INN

13354

Created by admin on Wed Apr 02 21:09:59 GMT 2025 , Edited by admin on Wed Apr 02 21:09:59 GMT 2025

PRIMARY

CAS

1314018-44-4

Created by admin on Wed Apr 02 21:09:59 GMT 2025 , Edited by admin on Wed Apr 02 21:09:59 GMT 2025

PRIMARY

FDA UNII

5UXW4B47R9

Created by admin on Wed Apr 02 21:09:59 GMT 2025 , Edited by admin on Wed Apr 02 21:09:59 GMT 2025

PRIMARY

Related Record Type Details


					TH565G8BVK

Betovumeline hydrochloride

SALT/SOLVATE -> PARENT

Amount:

Related Record Type Details


					5UXW4B47R9

Betovumeline

ACTIVE MOIETY

Comments:

The initial study to be conducted under this IND is Study ML-007-014, a hAME/mass balance study, in which ML-007 mixed with a microtracer of [14C]-ML-007 will be coadministered with fesoterodine as individual components in oral solution due to the nature of the clinical study.

Amount: